Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315
Summary
This episode explores how a longevity startup is building in Japan instead of Silicon Valley, with Okinawa serving as a strategic base because of its blue-zone reputation, aging population, and strong scientific ecosystem. The discussion centers on E.Kee Labs' pivot toward becoming a data infrastructure company for longevity and drug development, generating proprietary epigenetic and methylation datasets rather than consumer wellness products. Jason and Bilal also break down why Japan can be a capital-efficient place to start a biotech company, combining lower burn, smaller checks, grants, and local banking with regulatory advantages in regenerative medicine. A major theme is product-market fit: the company chose to abandon a growing clinic side business so it could focus on high-value use cases like aging research, drug discovery, and cell-therapy quality control. The episode also touches on biological age measurement, social robots as possible health tools through companionship, and the tension between intense startup work culture and long-term sustainable performance.
Key Takeaways
- 1The real moat in biological AI is proprietary data generation, not just the model.
- 2Japan can be a better place to build a longevity biotech startup than Silicon Valley in certain cases.
- 3Capital efficiency can make a smaller raise go further outside San Francisco.
- 4Finding product-market fit required narrowing the company’s scope to higher-value B2B use cases.
- 5Biological age is more useful as a research and trend metric than as a consumer optimization score.
- 6Longevity may also be influenced by emotional connection, not just molecules and diagnostics.
Notable Quotes
""We generate epigenetic data that don't exist yet for whoever wants to get a decision from it.""
""In AI for biology the moat is in data generation.""
""Japan has access to numerous therapies that you do not have access to in the US.""
""Great companies are bought not sold.""
""if the robots can actually create a link with with a person and have a feeling of care I would assume so""
""the intensity of 996 which is a Chinese thing not a Japanese thing is uh I think so but Japan also has similar traditional I guess especially in you know traditional company in Japan yeah you work late nights yeah""
""efficiency can beat hours but efficiency and hours can beat everything so just be ruthless about efficiency""
""I believe you should get seven hours and sleep even if you're like a crazy young person there's no reason not to""
Episode questions
Why did E.Kee Labs stop serving longevity clinics even though that business was growing?
Bilal says the clinic service brought in revenue, but it was distracting from the company’s core mission. The team wanted to focus on high-resolution data generation, which they believe creates more durable long-term value and better IP.
What makes Japan attractive for a longevity or regenerative-medicine startup?
Japan combines an aging population, strong science, and a more advanced regulatory framework for regenerative medicine than the US in some areas. The transcript also highlights OIST in Okinawa as a major talent and research hub.
How does E.Kee Labs use AI in its product?
They use AI after generating proprietary biological data, rather than relying only on public datasets. Their models help with drug discovery, patient stratification, and manufacturing quality control.
What does biological age mean in this conversation?
Biological age is presented as a biomarker-based estimate compared against a reference cohort, not a perfect literal age. Bilal says it is most useful for tracking trends and for research or clinical development, rather than as a consumer score to optimize aggressively.